| Best response, % |
FOLFOX- 4/FOLFOX-4+ placebo/ FOLFOX-4+ bevacizumab (n=937)
|
XELOX/XELOX+placebo/ XELOX+bevacizumab (n=967)
|
| Investigator |
IRC |
Investigator |
IRC |
|
| Response rate |
49.4 |
38.6 |
46.4 |
37.1 |
| CR |
1.5 |
1.2 |
2.0 |
2.0 |
| PR |
47.9 |
37.5 |
44.5 |
35.2 |
| SD |
34.3 |
38.1 |
32.2 |
36.8 |
| PD |
9.4 |
8.2 |
8.5 |
8.9 |
| Missing* |
6.9 |
15.0 |
12.9 |
17.2 |
|